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Abstract Lipid apheresis is at present well established in 
routine treatment of diverse hyperlipoproteinemias refrac-
tory to conventional dietary and medical regimens, espe-
cially in countries with high medical and socioeconomic 
standards. Severe familial hypercholesterolemia with ath-
erosclerotic vessel disease involving the coronary arteries 
is the most frequent indication for lipid apheresis as well 
as homozygous familial hypercholesterolemia before the 
development of cardiovascular complications.
In hyperlipoproteinemia (a) with progressive vessel dis-
ease, lipid apheresis is regularly accepted in Germany. The 
indication of apheresis in Refsum’s disease and the chylo-
micronemia syndrome is described.
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Indikationen zur Lipidapherese als eine Ultima ratio 
Behandlung refraktärer Hyperlipidämien
Zusammenfassung Die Lipidapherese ist mittlerweile 
gut etabliert als Routinebehandlung verschiedener Fett-
stoffwechselstörungen, die auf eine optimale diätetische 
und medikamentöse Therapie nicht ausreichend anspre-
chen und wird insbesondere in Ländern mit hohem medi-
zinischem und sozio-ökonomischen Standard häufig ein-
gesetzt. Die schwere familiäre Hypercholesterinämie mit 
arteriosklerotischer Gefäßerkrankung unter Einbezug der 
Koronarien stellt die häufigste Indikation dar, wie auch die 
homozygote familiäre Hypercholesterinämie vor Entwick-
lung kardiovaskulärer Komplikationen. In Deutschland 
wird bei der Hyperlipoproteinämie (a) die Indikation zur 
Apherese grundsätzlich akzeptiert, wenn eine progredient 
verlaufende Gefäßerkrankung vorliegt.
Der Einsatz zur Apherese bei Morbus Refsum und dem 
Chylomikronämie-Syndrom wird erläutert.
Schlüsselwörter Lipidapherese · Lipoproteinapherese · 
Morbus Refsum · Chylomikronämiesyndrom · 
Hyperlipoproteinämie (a) · Familiäre 
Hypercholesterinämie
Introduction
During the past 50 years, apheresis therapy has been applied 
successfully in patients with different disturbances of lipid 
metabolism. Various apheresis techniques have been devel-
oped, and currently have a well established place in the mul-
timodal therapy of severe lipid disorders. In some diseases, 
e.g., the chylomicronemia syndrome, apheresis is per-
formed as an emergency treatment in hospitalized patients; 
in other diseases, e.g., refractory hypercholesterolemia and 
hyperlipoproteinemia (a), maintenance apheresis therapy is 
required, usually on an ambulatory basis.
Plasma exchange has been the sole apheresis technique 
for more than 10 years for all disorders and is still frequently 
used in the chylomicronemia syndrome. The application of 
selective lipid apheresis techniques is preferred in patients 
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with refractory hypercholesterolemia and hyperlipoprotein-
emia (a), and is at present obligatory in most countries.
Lipid apheresis treatment except from emergency cases 
is indicated only in case of insufficient dietary and medical 
treatment. Because of the high costs and technical efforts, 
clinical use of lipid apheresis is mainly influenced by the 
economic prosperity of the social and health care system, 
which enables broad routine use only in industrialized coun-
tries. Furthermore, as most apheresis techniques have been 
invented in Japan and Germany, it is understandable that 
lipid apheresis techniques are applied there frequently in 
experimental studies as well as in clinical routine practice 
(see Table 1).
In Germany, e.g., health insurances are generally obliged 
to cover the costs of ambulatory treatment in patients with 
hypercholesterolemia and hyperlipoproteinemia (a) with 
progressive cardiovascular disease refractory to optimal 
dietary and medical treatment. Regional specialized com-
mittees of the so-called “kassenärztliche Vereinigung” have 
to evaluate the clinical course at yearly intervals. For all 
other indications, individual agreements have to be obtained 
for ambulatory patients. For in-hospital treatment, espe-
cially for the use of apheresis in emergencies, such appoint-
ments are usually not necessary.
Dietary and medical therapy
Patients with hypercholesterolemia usually respond poorly 
to pure dietary interventions. A moderate restriction of the 
dietary cholesterol, accompanied by high intake of vegeta-
ble fibers, may be considered.
Among several cholesterol-lowering drugs, statins have 
the most important role in the medical treatment of ele-
vated low-density lipoprotein (LDL) cholesterol. Usually, 
high-intensity statins (e.g., atorvastatin or rosuvastatin) are 
necessary, and low-potency statins (e.g., fluvastatin and 
pravastatin) may be an alternative for patients with intol-
erance to these drugs. Individual titration to the maximum 
dose resp. the max. tolerated doses is necessary.
In many patients with heterozygous familial hypercholes-
terolemia (FH), a reduction of LDL cholesterol by 40–50 % 
is possible with statin monotherapy, whereas homozygous 
patients usually respond poorly to statins [1–3].
Before considering apheresis, a combination drug ther-
apy has to be performed to reach a therapeutic goal of LDL 
cholesterol < 70 (or atleast < 100) mg/dl [4]. This includes 
the combination with the cholesterol absorption inhibitor 
ezetimibe, 10 mg/day, and the administration of bile acid 
sequestrants with cautious titration to an individually toler-
ated maximal dose to avoid gastrointestinal intolerance [1].
Nicotinic acid, which significantly reduces lipoprotein 
(a) (Lp (a)) levels by approximately 20 %, may be tried 
in hyperlipoproteinemia (a). After several studies failed 
to show an additional influence on clinical outcome when 
combined with statins, the drug is no longer available in 
several countries, e.g., in Germany.
Potential role of new drugs
Several highly potent new drugs have been currently devel-
oped, and will influence the indication for apheresis, be it 
the initiation of apheresis in new patients or the discontinu-
ation of maintenance treatment, especially in patients with 
statin intolerance.
For heterozygous patients, the development of PCSK9 
antibody therapy may offer an alternative to starting apher-
esis treatment or may improve lipid profile in patients with 
insufficient lipid profile on apheresis. Some PCSK9 anti-
bodies may get the European Medical Agency (EMA) and 
Food and Drug Administration (FDA) approval by the end 
of 2015. The impact on clinical outcome is a subject of cur-
rent studies [5, 6, 2].
In USA, antisense messenger RNA therapy, blocking 
Apo B synthesis (not available in Europe), is approved only 
for homozygous patients [6, 2]. Also only for homozygous 
disease, the Microsomal Transfer Protein MTP inhibitor 
lomitapide has recently been approved by the EMA [7, 8].
Up to now, no studies on clinical outcome are available, 
and significant hepatotoxicity has to be considered. There 
is still limited experience with the use of these drugs in 
patients on long-term apheresis. As especially in homozy-
gous patients, LDL apheresis even at a weekly interval usu-
ally does not normalize LDL cholesterol levels, these drugs 
should be considered as an additional treatment, at least in 
patients with progressive cardiovascular disease.
Table 1 Current indications for lipoprotein apheresis in Germany




 Homozygous with/without vascular disease
 Heterozygous with vascular disease
 Polygene with vascular disease
 Familial comb. hyperlipoproteinemia with vascular disease
Hyperlipoproteinemia (a) with progression of vascular disease
Applied only in exceptional situations
Graft vasculopathy after cardiac transplantation
Hyperlipoproteinemia (a) of end-stage renal disease with progres-
sive vascular disease
Sudden hearing loss (rheopheresis) [25]
Dry macular degeneration (rheopheresis) [26]
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by the German health insurance system already in the pres-
ence of the former target recommendation of < 100 mg/dl.
In the presence of the recently lowered therapeutic goal 
of < 70 mg/dl, it may be debatable whether an LDL choles-
terol level of 100 mg/dl should now be regarded as high 
enough for the initiation of apheresis. An individual analysis 
of the clinical records is indicated in such cases.
In the European countries, the guidelines for LDL apher-
esis still differ considerably. The British HEART UK LDL 
Apheresis Working Group recommended apheresis for an 
LDL cholesterol level of > 200 mg/dl in heterozygous FH 
patients, > 125 mg/dl in patients with Lp(a) > 60 mg/dl and 
progressive CHD, and > 350 mg/dl for homozygous FH 
patients.
The French guidelines recommended a treatment goal for 
LDL cholesterol of less than 100 mg/dl. The International 
Panel on Management of Familial Hypercholesterolemia 
recommends apheresis for heterozygous patients with symp-
tomatic CHD, if LDL cholesterol is more than 160 mg/dl.
In USA, where still few patients are under treatment, the 
FDA recommended an LDL cholesterol level of > 200 mg/
dl for heterozygous FH patients with CHD, > 300 mg/dl for 
heterozygous FH patients, and > 500 mg/dl for all homozy-
gous FH patients [1, 11, 12].
In Germany, all homozygous FH patients will have long-
term apheresis therapy starting at the age of 6–7 years at 
the latest, if possible. In patients with compound hetero-
zygous diseases, it may be controversial to start apheresis 
early if native LDL cholesterol levels are markedly less than 
500 mg/dl [3].
Hyperlipoproteinemia (a) and progressive vessel disease
Hyperlipoprotemia (a) has been identified as an independent 
atherosclerotic and atherothrombotic factor that potentiates 
the risk, if coincident with an elevated LDL cholesterol.
Severe hyperlipoproteinemia (a) may be also associated 
with accelerated and severe atherosclerotic disease in the 
absence of severe hypercholesterolemia, defined as isolated 
hyperlipoproteinemia (a) (see the following articles in this 
issue).
Lp(a) shows a considerable heterogenecity concern-
ing haplotypes, size, and single nucleotide polymorphism. 
More than 20 isoforms have been identified, of which some 
have been found associated with a strongly increased risk of 
atherosclerosis [13, 14].
Hyperlipoproteinemia (a) does not respond significantly 
to conventional drug therapy (see earlier in the text), apart 
from nicotinic acid, by which a reduction of more than 20 % 
can be achieved at a dose of 2 g daily without evidence of 
clinical benefit from outcome studies.
Familial hypercholesterolemia and the impact of serum 
cholesterol levels
Homozygous hypercholesterolemia usually occurs at a 
prevalence of 1:1,000,000 people or higher in special popu-
lations, and usually presents with total cholesterol levels 
in the range of 700–1200 mg/dl. For patients with homo-
zygous hypercholesterolemia, early initiation of apheresis 
therapy is recommended, to prevent severe juvenile vascu-
lar atherosclerosis [9]. Apheresis treatment should start at 
the age of 6–7 years at the latest and may be difficult in very 
small patients. As these patients have a dramatic increase 
of atherosclerosis, which develops frequently within the 
first decade of life, the proof of manifest atherosclerosis and 
clinical symptoms are usually not required for the clinical 
decision to start apheresis therapy [1].
Heterozygous FH patients usually present with total cho-
lesterol levels in the range of 280–500 mg/dl, showing a 
considerable variance and mostly responding well to drug 
therapy. Atherosclerotic disease becomes clinically mani-
fest frequently between the fourth and fifth decade of life, 
depending on total risk profile [10]. In patients with hetero-
zygous FH, refractory to dietary and drug treatment, apher-
esis is indicated only in the presence of clinically relevant 
disease, i.e., symptomatic atherosclerotic vessel disease of 
the coronaries, the arteries of the lower limbs, or the supra-
aortic branches. In Germany, additional statements by car-
diologists, neurologists, or angiologists are mandatory for 
the decision-making process. Genetic analyses are recom-
mended but are not obligatory for apheresis.
According to the current european atherosclerosis 
society/european society cardiology EAS/ESC guidelines, a 
target serum LDL cholesterol of < 70 mg/dl is recommended 
for patients with coronary heart disease (CHD) equivalent 
and that of < 100 mg/dl for patients at a high risk, e.g., with 
FH, without clinically relevant atherosclerotic vessel dis-
ease [4].
In patients with genetic disease, the same therapeutic 
goal should be achieved for both heterozygous and homo-
zygous FH patients regardless of age, according to a recent 
consensus panel on FH [10].
So, if comprehensive treatment in HC patients with mani-
fest coronary heart disease fails to establish a sufficiently 
low serum cholesterol profile, the financial burden may be an 
argument to withhold apheresis therapy from those patients 
in countries with low economic and medical standard. In 
highly industrialized countries, however, decision to perform 
apheresis should be made, to open a normal life expectancy 
in these patients by the interruption of lipid-induced highly 
accelerated atherosclerotic vessel disease [2].
If in Germany CHD patients have continuously elevated 
LDL cholesterol level (e.g., 120 mg/dl) despite optimal 
medical efforts, the costs of apheresis are usually covered 
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Duplex and B-mode ultrasound offer a noninvasive alter-
native to monitor changes in plaque size and stenosis diam-
eter representative only for selected vessel regions.
A pragmatic approach to define a significant progression 
may be the doubling of the degree of stenosis in moderate 
(i.e., < 50 %) stenoses or an increase of 20 % or more in ste-
noses > 50 %. A decline of more than 0.1 in ankle brachial 
pressure index may be suitable for disease of the lower limbs.
Also for the use of magnetic resonance or computed 
tomography (CT) angiography in coronary and noncardiac 
vessels, there is still no reliable quantitative approach for 
the evaluation of progression, the Agatstone score in cardiac 
CT included.
However, there is profound ethical concern in patients 
with late-stage atherosclerotic disease to concede aphere-
sis only after a progression has been documented; in these 
cases, the ultimate therapy should start before progression 
to an ultimate cardiac or vascular event occurs.
The strict pursual of such a protocol will possibly be 
lethal for many cardiac patients with severely reduced 
left ventricular function, advanced three-vessel coronary 
disease, or preceding coronary bypass operation and will 
often result in irreversible neurological defects or limb loss. 
Therefore, it seems adequate to consider the individual total 
cardiovascular risk of any further vascular complication in 
these cases.
Severe hypertriglyceridemia
Severe hypertriglyceridemia, defined as serum triglycer-
ide levels > 1000 mg/dl, is most frequently associated with 
the metabolic syndrome or poorly controlled type 2 diabe-
tes, and develops often in noncompliant patients. Genetic 
defects (see later in the text) are less frequent.
Especially in the chylomicronemia syndrome, triglycer-
ide levels of more than 5000 mg/dl can be observed with the 
occurrence of chylomicrons in serum. The clinical feature is 
variable; painful eruptive cutaneous xanthoma, neurologic 
signs of hyperviscosity syndrome due to impaired microcir-
culation along with central nervous symptoms, acute fatty 
lever degeneration, severe pancreatitis, and sometimes arte-
rial thromboembolic complications are common.
Secondary causes usually respond sufficiently to a strict 
hypocaloric diet and lipid-lowering drugs. By plasma 
exchange or lipid filtration, immediate relief of symptoms is 
achieved. If available, apheresis may be used as the primary 
treatment in suitable clinical settings and should be started 
early to prevent severe necrotizing pancreatitis and its com-
plications [18, 19].
Usually, three to six sessions result in a sufficient disease 
control, which can be maintained by strict dietary and drug 
Recent observation that treatment with PCSK9 antibod-
ies as well as with lomitapide and mipomersen leads to a 
significant improvement of hyperlipoproteinemia (a) has 
been surprising [7, 6, 15]. A protective effect of the treat-
ment with these news drugs with respect to atherosclerotic 
events still needs to be demonstrated, whereas the protec-
tive influence of LDL and Lp(a) apheresis has already been 
documented in several studies [16, 17].
It has to be discussed further under which circumstances a 
treatment with these drugs should be preferred to apheresis.
In Germany, the indication for apheresis in hyperlipopro-
teinemia (a) is accepted only in the presence of progressive 
CHD or CHD equivalent despite optimal correction of other 
risk factors, especially LDL cholesterol, if Lp(a) levels are 
> 60 mg/dl (0.6 g/l) in accordance with the Joint Federal 
Committee guidelines.
Definition of relevant disease progression is often diffi-
cult and is still a matter of discussion. As no general defi-
nition of atherosclerotic disease progression is available, 
results of various diagnostic procedures as well as clinical 
events can be used. The decision as to at which point pro-
gression becomes significant and clinically relevant is often 
controversial. Hard end points frequently used in outcome 
studies are shown in Table 2.
Table 2 Significant clinical end points (selected) indicative of pro-
gression of atherosclerotic vessel disease







First-time occurrence of clinical symptoms 
(diagnosis assured)





Operative procedures mainly on carotid 
arteries
PTA/stent




of the lower limb
Operative procedures
PTA/stent






 Truncus coeliacus stenosis
 Mesenterial infarction
 Renal artery stenosis
aCave different use the term cardiovascular events as coronary or 
cardiac and vascular events
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Refsum’s disease
Classic Refsum’s disease (heredopathia atactica polyneu-
ritiformis) is an autosomal recessive disorder of peroxy-
somal function, associated with accumulation of phytanic 
acid, caused by a defect in phytanoyl-coA-hydroxylase, 
which is central in the metabolism of this branched-chain 
fatty acid. Several patients exhibit more than one genetic 
defect, involving other enzymes.
The typical clinical signs are retinitis pigmentosa, periph-
eral polyneuropathy, cerebellar ataxia, and progressive 
hearing loss, progressing to deafness, blindness, and cardiac 
conduction defects. Clinical diagnosis is usually established 
in the third to fourth decade of life, when clinical picture 
becomes more significant and is confirmed by elevated lev-
els of phytanic acid in serum.
Most patients respond sufficiently to diet. Phytanic acid 
serum concentrations > 100 mg/dl can be considered as 
toxic. Plasma exchange and LDL apheresis techniques (e.g., 
lipid filtration or heparin-induced extracorporeal ldl pre-
cipitation H.E.L.P.) can be applied because phytanic acid is 
transported in plasma in LDL particles.
Long-term apheresis treatment may be indicated in 
patients with progressive clinical symptoms to prevent 
life-threatening complications, blindness, deafness, and 
complete disabling. Disease progression is usually halted, 
and some patients have moderate improvement of different 
clinical symptoms. It can be assumed that 10–20 patients 
are currently on maintenance apheresis in Germany.
Apheresis may also be used in acute critical situations 
that may develop, e.g., in case of short-term weight loss 
[21–24].
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